PROCESS  FOR  THE  PREPARATION  OF  CASPOFUNGIN  ACETATE  AND INTERMEDIATES The present disclosure discloses a process for preparation of caspofungin and its intermediates

The present invention provides a process for the preparation of Teriflunomide (Formula I). The present invention describes the synthesis of Teriflunomide without isolating the intermediate Leflunomide. Teriflunomide is prepared from 5 Methyl isoxazole 4 carboxylic acid by converting to its acid chloride and coupling...

The present invention discloses the pharmaceutically acceptable salt of Brinzolamide as Brinzolamide maleate and process for the preparation of the same and its polymorph.

The present disclosure relates to a highly specific and sensitive method of detecting host cell impurities in a biological sample by using quantitative real time polymerase chain reaction (qPCR).The present disclosure also provides novel designed primer and probe to amplify only the specific Alu family of dispersed ...

The present disclosure relates to a process for detecting and optionally quantifying an analyte in a sample in the presence of a soluble target of the analyte. The soluble target forms a complex with the analyte and thus may interfere in determining the total analyte concentration. The process of the present inventi...

The present disclosure provides for processes for preparation of Glatiramer acetate. The present disclosure also relates to preparation process of peptide based polymer mixtures, where each polymer is arranged in a random manner comprising the amino acids: L-Glutamic acid, L-Alanine, L-Tyrosine, and L- Lysine. This ...

The present disclosure relates to processes for the preparation of 2-amino-1,3-propane diol compounds and their hydrochloride salts. Particularly, the present disclosure relates to processes for synthesizing 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol and its hydrochloride salt 2-amino-2-(2-(4-octylphenyl)eth...

Present disclosure discloses the commercially viable process for the preparation of Deferasirox and its polymorph with. Disclosed process involves the preparation of Deferasirox via metal salt of the corresponding intermediate and deferasirox metal salt.

The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy and more specifically to nucleotide sequences encoding the fusion proteins wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counter...

The current disclosure discloses stereo selective bioreduction of keto intermediates of various pharmaceutically active compounds to their corresponding hydroxyl compounds by microbes.

The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.

The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1(D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM). ...

A complex comprising: an insulin conjugate comprising a native insulin or insulin polypeptide analog thereof having an A chain and B chain of amino acids conjugated to a modifying moiety, wherein the insulin polypeptide analog has the structure of a human native insulin with one or more amino acid additions, del...

The present disclosure relates to crystalline forms and amorphous form of Rosuvastatin Acetonide Calcium which is known by chemical name (3R,5S,6E)- 7 - [4- (4-Fluoro- phenyl) -6-isopropyl-2-(methanesulfony l- methyl-amino ) - pyrimidin-5-yl) vinyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetic acid calcium salt. The disclos...

The present invention relates to a stable pharmaceutical formulation of a pharmaceutically active anti-cd20 antibody such as e.g. BVX20 for intravenous (IV) administration. The formulation of the present invention is found to be stable for up to 24 months at 2-80C. In particular, the present invention relates to sin...

The present disclosure relates to a process of identification and isolation of sorbitol dehydrogenase promoter from Pichia pastoris. Further  the present disclosure also relates to expression of heterologous proteins under the control of Sorbitol dehydrogenase promoter in Pichia pastoris.

The present invention discloses novel process for the preparation of mixture of polypeptides comprising L-Glutamaic acid, L-Alanine, L-Tyrosine, and L-Lysine.by employing circular dichroism as a guidance tool.

he present disclosure provides solution to the problems involved in determining the crystallinity of sirolimus. More particularly, the instant disclosure is successful in providing a method to determine crystallinity of sirolimus or its analogues using Near-Infrared [NIR] spectroscopy. Also, the instant disclosure p...

ABSTRACT: The present invention provides an improved process for expressing, isolating and purifying PEG-G-CSF from a G-CSF producing microorganism. The invention also relates to a method of expression of G-CSF in E. coli, including sequence, plasmids, expression vectors and host cells for use in such an improved m...

The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in Pichia. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated ...

The present invention relates to a process for preparing N~(trans4~ isopropylcyclohexylcarbonyl)-D-Phenylalanine Form C comprising the steps of : (a) suspending N-(trans4~isopropylcyclohexylcarbonyl)-D-Phenylalanine methyl ester in water or a water miscible solvent; (b) treating the suspension with a base; ( (...

The present invention relates to the purification of daptomycin. More specifically, the invention relates to a simplified and optimized purification process of daptomycin from a fermentation broth by chromatographic procedures enabling high yields, selectivity and purity of the desired end product. The daptomycin is...

The invention relates to a process for the recovery of a macrolide in substantial pure form comprsing: a) treatment of an Impure or crude macrolide with water immiscible solvent, b) optional concentration of the mixture, c) treatment with ammonia gas to phase out impurities, d) separation of impurities, e) opti...

A process for synthesis of a compound of formula I using microwave irradiation. FORMULA I

The present invention demonstrates the utility of ion pairing agents in the preparative scale of purification. More particularly, the invention relates to the usage of ion pairing agents in RP preparative non linear chromatography enabling high purity of the desired end product. The invention shows that ion-pairing ...

The present invention relates to a process for purification of mycophenolic acid comprising steps of: (a) extracting mycophenolic acid solution in a first water immiscible solvent with a first aqueous base to selectively remove polar impurities; (b) extracting the water immiscible layer from step (a) with a second a...

ABSTRACT The present invention is in relation to a process for preparation of HMG-CaO reductase inhibitor. More particularly, the present invention provides a process for preparation of (3R,5S,6E) 6-{2-[4-(4-Fluoro-phenyl)-6-isopropyl 2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-2,2-dimethyl-[l,3]dioxan-...

The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formul...

A procedure for chromatography wherein the sample solution is prepared in a solvent or mixture of solvents having elution strength greater than the mobile phase, comprising: > equilibrating the stationary phase with a weak mobile phase; > injecting the sample solution in the column; > elution wherein mobile phase...

The present invention relates to the process of preparation of granules of lactulose, isphagula husk and microcrystalline cellulose. The present invention further relates to the process of the preparation of granules using lactulose solution optionally in combination with adsorbent or suspending agent as a binder so...

A method of making N-terminal methionine free polypeptide in ecombinant microbial host cell and pharmaceutical compositions along with one or more pharmaceutical excipients for management of various therapeutic disorders

The present disclosure provides a crystalline form of orlistat, particularly form A of orlistat. The characterization of said form is performed using X-ray diffraction studies, IR and Differntial Scanning Calorimetry melting endotherm studies. Also, the disclosure provides a simple process to arrive at said crystall...

A stable pharmaceutically formulation containing antibody, a buffer, a non-ionic surfactant, and a lyoprotectants/cryoprotectants. Also disclosed are associated methods for preparing, storing, and using such formulations.

The present disclosure provides solution to the problem associated in the preparation of duloxetine hydrochloride. This disclosure is successful in preventing the racemization and thereby prevents the formation of unwanted isomer of duloxetine hydrochloride. In addition, the disclosure provides a simple technique fo...

The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.

The present invention relates to a method for the preparation of thiazolidinedione derivatives by reducing intermediates of thiazolidinedione derivatives having double bonds.

The invention provides a process for the production of lipase inhibitors via an improvised fermentation process characterized in that a combinatorial feeding of linoleic acid or its esters or salts thereof and an omega-9 fatty acid, preferably oleic acid and/or its derivatives is employed during said process resulti...

The present invention is suecessful in providing a suitable process for the isolation and purification of geldanamycin. The process provided in the instant invention is easy to scale-up, industrially safe and will give high yield and productivity.

ABSTRACT The present invention relates to a method of purifying human growth hormone from a mixture containing at least one related impurity; and a purified growth hormone with purity of at least 85%.

The instant disclosure provides a method for purification of peptides by chromatographic techniques. The proposed methodology will help in addressing the problems associated in purifying biological protein products emerging from the evolving biotechnology industry.

ABSTRACT The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamate, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and ins...

The invention relates, interalia, to the field of purification of peptides, notably cyclic or non-cyclic peptides their analogs or derivatives thereof. More particularly, the invention relates to a simplified and optimized purification process of cyclic peptides from a composition comprising the said peptide and at ...

The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide whi...

The present invention relates to a novel process for the preparation of the HMG-CoA reductase inhibitor, fluvastatin, more specifically to a process for the preparation of amorphous form of fluvastatin sodium.

This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-...

The present invention demonstrates the utilization of halide anions such as iodates, periodates, bromates, chlorates, perchlorates and other forms of halides as supplements in fermentation media for the production of secondary metabolites employing fungal systems such as systems Aspergillus, Rhizopus, Streptomyces e...

A method for preparing a novel enzyme Enzyme Preparation For Improved Baking Quality which comprises of: . a. preparing an inoculum ofRhizopus sp., b. preparing an inoculum of Aspergillus sp., c. mixing the grown inoculum ofRhizopus sp. d. sterilizing a solid state nutritive matrix, e. mixing the said steril...

The invention relates to methods of separation and/or purification of impurities yielding a purified heterologous protein product devoid of related impurities or with substantially minimal quantities of such glycosylated impurities. More specifically, the invention relates to the identification of glycosylated forms...

The disclosure relates to method of reducing O-glycosylation levels of the insulin or insulin analog precursor molecule produced by Pichia sp. The present disclosure provides genetically engineered knock-out strains of methylotrophic yeast including Pichia and especially Pichia pastoris by disruption of Protein mann...

The present invention is related to crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate, which is a Rosuvastatin Intermediate. The invention also provides a method for the preparation and isolation in the crystalline form of the Rosuv...

The process described herein discloses purification process of a secondary metabolite produced by fermentation route. The process involves selective removal of impurities at various stages of washings, charcoalization followed by crystallization. The product is closely related to class of echinocandins and is found ...

The present invention relates to crystalline forms of atorvastatin hemi-magnesium salt and a process for the preparation of crystalline forms. It also relates to a pharmaceutical composition comprising these crystalline forms or combinations thereof optionally along with pharmaceutically acceptable excipients. ...

ABSTRACT The present invention relates to the preparation of insulin compounds including their analogs or derivatives thereof from their corresponding precursor forms by a one step enzymatic reaction involving the combinatorial and concurrent use of optimal quantities of trypsin and carboxypeptidase B that work syn...

The present invention provides a process of preparing tetrahydrolipstatin, comprising catalytical hydrogenation of lipstatin in polyethylene glycol. Optionally polyethylene glycol is mixed with an organic solvent selected from a group of lower alcohols, non polar solvents and ethers. The invention further includes p...

The present invention provides crystalline forms B4 and B5 of atorvastatin hemi magnesium salt. In addition, it also provides a process for preparation of crystalline forms B4 and B5 of atorvastatin hemi magnesium salt.

The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and resin mediated synthesis. Fig (2)

The invention provides a complex including a cation and an insulin compound conjugate. The insulin compound conjugate includes insulin compound, such as human insulin or an analog thereof, conjugated to a modifying moiety, such as a polyethylene glycol moiety. The invention also includes solids and pharmaceutical co...

rhe present invention relates to an anti CD6 antibody that binds to the SRCR domain l(CDl) orCD6 present on the surface of thymes pithead cells, monocytes, activated T cells and a variety of other cells types. The invention further relates to methods of inhibiting proliferation off cells without blocking the interac...

ABSTRACT The present invention provides an improved process for the preparation of intermediates involved in the preparation of rosuvastatin. Particularly, the proposed invention is able to overcome the disadvantages associated with the known methods. Thus, the instant invention provides a process which is clean, e...

ABSTRACT The present invention relates to methods of synthesizing oligomeric compounds, and more particularly to methods of synthesizing oligomer compounds comprising polyethylene glycol moieties. The present invention provides improved methods for synthesizing oligomers comprising polyethylene glycol moieties. Met...

The present disclosure provides methods of developing a specific immunoassay for the Pharmacokinetic assessments of peptides, peptide oligomer and polymer including Glatiramer Acetate (GA), also known as Copolymer 1, Copolymer-1, Cop 1 or Cop in the clinical and pre clinical matrices.

The disclosure relates to a process of obtaining a fully folded two chain insulin glargine that require no further processing to make it functionally active. The present disclosure discloses a surprising effect of over expression of Kex2p intracellularly under the control of inducible FLD1 promoter in the host Pichi...

The present invention provides a novel method for producing compound of formula (I) or any of its salt form, by solid state fermentation, optionally using fed-batch technique by culturing microorganisms capable of producing the compound of formula (I).

Methods are disclosed for preparing compounds of Formula I: where R1,R3, and R are independently hydrogen or C1 to C4 alkyl, and R is: where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or where R , R and R are independently hydrogen or C| to C4 alkyl; or the esters or pharmacologically a...

The present invention provides an industrial method production of amorphous posaconazole. The present invention also relates to a method for production of the posaconazole via and novel crystalline forms of posaconazole intermediate. More particularly the present invention relates to novel crystalline forms of posac...

The present invention provides an industrial method for production of silodosin which is useful for a therapeutic agent for dysuria associated with benign prostatic hyperplasia. The production of silodosin is characterized by mixing (R) l (3 hydroxypropyl) 5 (2 (2 (2 (2 2 2 trifluoroethoxy) phenoxy) ethyl amino) pro...

A novel process for the preparation of compounds of formula (I): Rx = CN, OP (P=any suitable protecting group), alkyl, aryl or hetroaryl, R: = Alkyl or aryl by reacting a compound of formula (II): Rt = CN, OP (P=any suitable protecting group), alkyl, aryl or hetroaryl, R2 = Alkyl or aryl with a reducing agent, sodiu...

A novel process for the production of 5-(4-Fluro-phenyl)-2-isopropyl-4-phenyl-1-(3,5,7-trihydroxy-heptyl)-1H-pyrolle-3-carboxylic acid phenylamide hemicalcium salt, its stereoisomer or polymorph from a (6-{2-[2-(4-Fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrolidin-1-yl]-ethyl}-2-phenyl- [1,3,2] dioxabo...

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-...

The present invention relates to the stable acid addition salts of Bosentan that are useful for the purification of Bosentan base. In particular  the Bosentan acid additional salt is selected from Bosentan citrate and Bosentan tartarate.

The present invention relates to a method or process for controlling inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post translational modification in the presence of an elevated total concentr...

The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T helper 17 (Th17) and/or T helper 1 (Th1) T lymphocytes (T cells). In particular the present disclosure relates to use of anti CD6 antibody for treatment of disease conditions mediated by auto reactive Th17 and ...

The present invention provides for crystalline Form B1 of N-(3-carboxyl-1-oxopropyl)- (4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt crystalline Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4- amino-2R-methyl butanoic acid ethyl ester sodium salt a novel proc...

A method of preparing Indian bread having nutritive value and organoleptic value comprising the steps of mixing a dough with oligosaccharide, said oligosaccharide being Isomalto-oligosaccharideI

The present invention discusses a novel process for the synthesis of [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1 H-pyrrole-l-heptanoic acid hemi calcium, atorvastatin form V. The compound so prepared is useful as inhibitors of the enzyme HMG-CoA reducta...

The insulinotropic peptide, exendin-4, is overexpressed in Pichia pastoris using a codon optimized encoding sequence with a optional signal peptide and/or propeptide. The expression of the exogenous gene is driven by the methanol inducible promoter AOX. The purified peptide from the recombinant organism is a...

The present invention provides a Fatty acid salt particles having a size distribution wherein the particles are from about 1 to about 1,000 microns in diameter, use of the particles in pharmaceutical compositions, as well as method and using the particles and composition.

The present invention relates to a pure form of rapamycin with a total impurity content less than 1,2% ; a process for recovery and purification of rapamycin comprising steps of (a) treating the fermentation broth, extracts or solutions containing rapamycin with water immiscible solvent and concentration; (b...

A process of manufacturing sodium salt of Mycophenolic acid of formula I comprising, a. reacting the compound of formula I with one among dicyclohexyl amine, dibenzylamine or ammonia to provide an intermediate of a dicyclohexyl amine salt, a dibenzylamine salt or an ammonium salt,b. reacti...

A novel compound of formula (I) and a process for the preparation of compounds of formula (I): by reacting a compound of formula (II): Formula (III): with a compound of formula (III) where R1 and R2 are any suitable alkyl group, preferably C2H5 or R1 and R2 can join together to form any cyclic st...

The invention relates to peptide mass fingerprinting technique for the proteins such as Human insulin and insulin analogs. The insulin analogues can vary at least by one amino acid, which is elusive to distinguish by currently available analytical methods. The invention further allows sequence confirmation of the pe...

The present invention describes the integration of preparative crystallization, crystal separation, crystal washing and freeze-drying processes into single continuous process using pressure filtration. The process facilitates time reduction, and outlines the novel design of using multiple organic solvent washes and ...

Disclosed is a method of controlling postprandial blood glucose levels in a subject. The method includes orally administering to a subject an orally administrable oligoethylene glycol conjugate of insulin or an orally administrable insulin fusion protein. Oral administration is done during a time period from about 5...

The present invention relates to a process for purification of non-glycosylated insulin analogues from a mixture comprising glycosylated and non-glycosylated proteins by removal of glycosylated proteins. The removal is achieved by combination of two RP-HPLC steps.

The present invention provides for a specific and sensitive bio-analytical method for detection of insulin or insulin analogues in plasma serum or any other biological fluid wherein the insulin or insulin analogues are labelled with a stable isotopic nitrogen for detection by the use of solid phase extraction and li...

The present invention discloses a key mechanism of action of Itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.

The present invention provides for crystalline Dapagliflozin butane -12- diol solvate (VIII) crystalline Dapagliflozin (S) butane -12- diol solvate (VIIIa) and Dapagliflozin (R) butane -12- diol solvate (VIIIb). The present invention also provides industrial methods for production of crystalline Dapagliflozin butane...

The present invention discloses rapid and cost-effective method of de-glycosyation of a glycoprotein wherein glycoprotein is combined with anionic surfactant and reducing agent and non-ionic surfactant in order to obtain stable denatured glycoprotein. An endoglycosidase is further added to denatured glycoprotein to ...

The present invention discloses a method for crystallizing recombinant Human Insulin at lab and manufacturing scale in the presence of zinc chloride and sodium chloride mixture, higher concentration of organic solvent (IPA-19 to 25 million) and adjusting the pH to 5.0 at a faster rate(=5 minutes) .The method further...

The present invention provides novel crystalline forms B1 & B2 of linagliptin intermediate of structural formula V and methods for production of novel crystalline form of linagliptin intermediate represented by the following structural formula V.

The present invention provides for novel co-crystals of lenalidomide. The present invention particularly provides for novel cocrystals of lenalidomide with Resorcinol, Methyl paraben and Saccharin. The present invention also provides for the processes for the production of cocrystals of lenalidomide with Resorcinol,...

The present invention relates to the efficient solid-phase synthesis of Icatibant represented by Formula (I). The present invention relates to an efficient process for the preparation of Icatibant by sequential coupling employing solid phase approach. It involves sequential coupling of protected amino acids to prepa...

The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±) – 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline d...

The present invention provides for purification of liraglutide using selective ion-pairing agents in the reversed phase-high performance liquid Chromatography, for purifying crude liraglutide from closely related impurities.

The present invention relates to the efficient solid-phase synthesis of liraglutide represented by Formula-I. The present invention relates to an efficient process for the preparation of liraglutide by sequential coupling employing solid phase approach. It involves sequential coupling of protected amino acids to pre...

The present invention provides the use of anti-CD6 antibodies that specifically bind to domain 1 of CD6 for treating effects of a coronavirus or bacterial agent and particularly COVID-19 and variants thereof. The anti-CD6 antibodies of the present invention exhibit therapeutic activity by reducing the overactive imm...

The present invention relates to solvates of Vortioxetine and pharmaceutically acceptable salts thereof. This invention further relates to Vortioxetine trifluoroacetate salt, its preparation, and its use for the preparation of Vortioxetine and its pharmaceutically acceptable salts and/or solvates. ...

The present invention relates to an immobilized deacylase in cross-linked cell aggregates, a preparation method and use thereof in deacylation of echinocandins. The immobilization of deacyalse in cross-linked cell aggregates comprises the step of • Production of Deacyalse by fermentation • Aggregation of cells • Cro...

The present invention provides for novel and improved liraglutide precursor purification processes of liraglutide precursor using selective unit operation steps and selective pH gradients in the reversed phase-high performance liquid Chromatography, for purifying crude liraglutide precursor from closely related impu...

The present invention relates to an improved process for preparing daptomycin, by providing a fermentation broth of daptomycin and adjusting a pH to precipitate the daptomycin, subjecting the solution through microfiltration and obtaining the microfilter retentate comprising precipitated daptomycin. The handling vol...

The present invention relates to novel crystalline form of ivacaftor, which is characterized by the XRD, TGA, DSC, DVS and NMR data and further provides a process for preparing the novel crystalline form of ivacaftor, which is cost effective and commercially scalable.

The present invention provides a process for the preparation of Liraglutide comprising the following steps: a) Acylation of linear peptide component of Liraglutide in a solvent using Pal-Glu(Y)-OR in presence of a base to form R-protected Liraglutide b) De-protection of R group using an acid in presence of an amino ...

The present invention is related to processes for preparing Ruxolitinib and its pharmaceutically acceptable salts. These processes for the preparation of Ruxolitinib are cost-effective and are suitable for industrial production.

The present invention provides for novel synthetic approach of solid phase synthesis of peptides with C-terminal Aspartic acid by anchoring the side chain carboxylic group of aspartic acid to the solid support to avoid the formation of various impurities and thus resulting in higher yield and ease the purification p...

The present invention provides for novel amorphous solid dispersions of form of cabozantinib malate, and a pharmaceutically acceptable excipient and process for the preparation of cabozantinib malate. The invention also provides a novel crystalline polymorph of cabozantinib.

The present invention relates to a process for preparation of glucagon comprising condensing a fragment-1 (24 mer providing amino acid residues 6-29 of glucagon) with a fragment-2 (5- mer providing amino acid residues 1-5 of glucagon) in the presence of a coupling agent to obtain a protected glucagon, deprotecting t...

ABSTRACT PROCESS FOR PREPARATION OF ADAGRASIB The present invention provides a novel intermediate of Adagrasib and its process for preparation. The present invention also relates to process for the preparation of Adagrasib and its pharmaceutically acceptable salts thereof.